Edition:
India

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

11.97USD
10:44pm IST
Change (% chg)

$0.27 (+2.31%)
Prev Close
$11.70
Open
$11.72
Day's High
$11.99
Day's Low
$11.53
Volume
42,124
Avg. Vol
335,796
52-wk High
$23.03
52-wk Low
$6.81

Latest Key Developments (Source: Significant Developments)

AMAG Pharma Announces Settlement Agreement With Caligan Partners LP
Tuesday, 8 Oct 2019 

Oct 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT WITH CALIGAN PARTNERS LP.AMAG PHARMACEUTICALS INC - BOARD OF DIRECTORS HAS APPOINTED PAUL FONTEYNE, FORMER CHIEF EXECUTIVE OFFICER OF BOEHRINGER INGELHEIM USA.AMAG PHARMACEUTICALS INC - BOARD OF DIRECTORS HAS APPOINTED DAVID JOHNSON, PARTNER AND CO-FOUNDER OF CALIGAN.AMAG PHARMACEUTICALS INC - FOLLOWING 2020 ANNUAL MEETING, SIZE OF BOARD WILL REVERT TO NINE DIRECTORS.AMAG PHARMACEUTICALS INC - APPOINTMENT OF FONTEYNE AND JOHNSON TEMPORARILY EXPANDS SIZE OF AMAG BOARD TO 11 DIRECTORS.AMAG - CALIGAN HAS WITHDRAWN ITS PENDING CONSENT SOLICITATION AND AGREED TO A CUSTOMARY STANDSTILL, VOTING COMMITMENT, AND RELATED TERMS.AMAG PHARMACEUTICALS INC - WILL INCLUDE FONTEYNE AND JOHNSON AS CANDIDATES IN COMPANY'S PROXY STATEMENT FOR COMPANY'S 2020 ANNUAL MEETING.AMAG PHARMACEUTICALS INC - 10 OF THE 11 DIRECTORS ON BOARD ARE INDEPENDENT, FOUR OF WHOM HAVE BEEN APPOINTED WITHIN PAST SIX MONTHS.  Full Article

AMAG Pharma Announces Launch Of Female Libido Injectable Therapy Vyleesi
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES COMMERCIAL AVAILABILITY OF VYLEESI™ (BREMELANOTIDE INJECTION).AMAG PHARMACEUTICALS INC - VYLEESI (BREMELANOTIDE INJECTION) IS NOW COMMERCIALLY AVAILABLE THROUGH SPECIALTY PHARMACIES, AVELLA AND BIOPLUS.  Full Article

Caligan Partners Reports A 10.3% Stake In Amag Pharmaceuticals As Of Aug. 6
Friday, 16 Aug 2019 

Aug 15 (Reuters) - Caligan Partners LP::CALIGAN PARTNERS LP - BELIEVE SECURITIES OF AMAG PHARMACEUTICALS ARE UNDERVALUED & REPRESENT AN ATTRACTIVE INVESTMENT OPPORTUNITY.CALIGAN PARTNERS LP REPORTS A 10.3% STAKE IN AMAG PHARMACEUTICALS <<>> AS OF AUG. 6 - SEC FILING .CALIGAN PARTNERS - MAY DEVELOP PLANS OR MAKE PROPOSALS REGARDING POTENTIAL STRATEGIC REVIEW OR SALE PROCESS INVOLVING AMAG OR ITS ASSETS.CALIGAN PARTNERS LP - INTEND TO COMMUNICATE WITH AMAG PHARMACEUTICALS' MANAGEMENT & BOARD ABOUT RANGE OF OPERATIONAL & STRATEGIC MATTERS.CALIGAN PARTNERS - MAY DEVELOP PLANS, MAKE PROPOSALS REGARDING AMAG'S MANAGEMENT, COMPOSITION OF BOARD OF DIRECTORS.CALIGAN PARTNERS - MAY DEVELOP PLANS, MAKE PROPOSALS REGARDING AMAG'S DIVIDEND POLICY.CALIGAN PARTNERS LP - INTEND TO COMMUNICATE WITH AMAG PHARMACEUTICALS' OTHER SHAREHOLDERS OR POTENTIAL ACQUIRERS, SERVICE PROVIDERS, FINANCING SOURCES.  Full Article

AMAG Pharmaceuticals Q2 Revenue $78.1 Million Versus $146.3 Million
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $78.1 MILLION VERSUS $146.3 MILLION.Q2 REVENUE ESTIMATE $92 MILLION -- REFINITIV IBES DATA.2019 FINANCIAL GUIDANCE LOWERED: EXITING MAKENA INTRAMUSCULAR MARKET AND REMOVING MILESTONE REVENUE.VYLEESI ON-TRACK FOR NATIONAL LAUNCH IN SEPTEMBER.SEES 2019 TOTAL REVENUE $325 MILLION - $355 MILLION.SEES 2019 OPERATING LOSS $286 MILLION - $276 MILLION.  Full Article

AMAG Pharmaceuticals Announces Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $41 MILLION.Q2 REVENUE ESTIMATE $92 MILLION -- REFINITIV IBES DATA.2019 FINANCIAL GUIDANCE LOWERED: EXITING MAKENA INTRAMUSCULAR MARKET AND REMOVING MILESTONE REVENUE.VYLEESI ON-TRACK FOR NATIONAL LAUNCH IN SEPTEMBER.SEES 2019 TOTAL REVENUE $325 MILLION - $355 MILLION.SEES 2019 OPERATING LOSS $286 MILLION - $276 MILLION.  Full Article

AMAG Pharmaceuticals Says Q1 Loss Per Share $3.54 From Cont Ops
Tuesday, 7 May 2019 

May 7 (Reuters) - AMAG Pharmaceuticals Inc ::REPORTS Q1 2019 REVENUE $75.8 MILLION.AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $3.54 FROM CONTINUING OPERATIONS.Q1 REVENUE $75.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $90.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.REAFFIRMED 2019 FINANCIAL GUIDANCE.AS OF MARCH 31, 2019, COMPANY'S CASH AND INVESTMENTS TOTALED $266.5 MILLION, AND LONG-TERM TOTAL DEBT TOTALED $320.0 MILLION.  Full Article

AMAG Pharmaceuticals Reports Results From Prolong Trial Evaluating Makena
Friday, 8 Mar 2019 

March 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM THE PROLONG TRIAL EVALUATING MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION).AMAG PHARMA - PROLONG TRIAL DID NOT DEMONSTRATE A STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN TREATMENT AND PLACEBO ARMS FOR CO-PRIMARY ENDPOINTS.AMAG PHARMACEUTICALS INC - PLAN TO CONDUCT ADDITIONAL SUB-GROUP ANALYSES OF PROLONG DATA.  Full Article

AMAG Reports Fourth Quarter And Full Year 2018 Results
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q4 REVENUE $88.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $96.5 MILLION.REAFFIRMS 2019 FINANCIAL GUIDANCE AND ANNOUNCES CONSOLIDATION OF WOMEN'S HEALTH AND MATERNAL HEALTH SALES FORCES.FY2018 EARNINGS PER SHARE VIEW $-5.71, REVENUE VIEW $484.7 MILLION -- REFINITIV IBES DATA.EXPECTS TO RECORD A ONE-TIME RESTRUCTURING CHARGE OF APPROXIMATELY $6 MILLION IN Q1 OF 2019..QTRLY LOSS PER SHARE $0.64.  Full Article

Palatin Technologies Say FDA Has Extended Prescription Drug User Fee Act Date For Vyleesi By Three Months
Monday, 7 Jan 2019 

Jan 7 (Reuters) - AMAG Pharmaceuticals Inc ::PALATIN TECHNOLOGIES - FDA HAS EXTENDED THE PRESCRIPTION DRUG USER FEE ACT DATE FOR VYLEESI BY THREE MONTHS TO JUNE 23, 2019..PALATIN TECHNOLOGIES - FDA-REQUESTED FREQUENT-DOSING STUDY WITH PREMENOPAUSAL VOLUNTEERS ASSESSING SHORT TERM DAILY USE OF VYLEESI HAS BEEN INITIATED.PALATIN TECHNOLOGIES INC - STUDY RESULTS ARE ANTICIPATED TO BE SUBMITTED TO THE FDA PRIOR TO THE UPDATED PDUFA DATE OF JUNE 23, 2019..  Full Article

AMAG Pharmaceuticals Announces Preliminary 2018 Results
Monday, 7 Jan 2019 

Jan 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL GUIDANCE.SEES FY 2018 REVENUE $471 MILLION TO $476 MILLION.SEES Q4 2018 REVENUE $85 MILLION TO $90 MILLION.FY2018 REVENUE VIEW $491.3 MILLION -- REFINITIV IBES DATA.Q4 REVENUE VIEW $101.8 MILLION -- REFINITIV IBES DATA.  Full Article

Amag settles with activist Caligan, adds two board directors

Amag Pharmaceuticals Inc , whose shares have tumbled more than 45% in the past year, on Tuesday agreed to add two directors proposed by Caligan Partners after the hedge fund pressured the drugmaker to conduct a strategic business review.